Department of Oncology, Beijing You'an Hospital, Capital Medical University, Beijing, 100069, China.
Beijing iGandan Foundation, 103-5C16-1, 1F, Building 1, No. 16, South Third Ring West Road, Fengtai District, Beijing, 100069, China.
BMC Gastroenterol. 2022 Jul 24;22(1):351. doi: 10.1186/s12876-022-02425-4.
Liver cancer is a severe public health problem worldwide, and it creates a relatively higher disease burden in China than in the Western world. Despite achieving notable progress in China, potential differences in some aspects of medical services for liver cancer may persist across different regions and hospitals. This warrants serious consideration of the actual status of and barriers to liver cancer treatment. We intended to explore the present status of and obstacles in liver cancer treatment especially for advanced-stage liver cancer.
In February 2021, a national multicenter cross-sectional study was conducted among 1500 doctors from 31 provinces of mainland China using a self-administered online questionnaire. Participants completed the questionnaire about their general information, perspectives on the current status of liver cancer treatment, and expectations for future treatment. Chi-square and logistic regression analyses were performed to explore the differences associated with the regions, doctors' professional ranks, and hospital levels.
Treatment conditions, medications, and treatment strategies were inconsistent across different economic regions and hospital of different levels. With respect to obstacles in treatment, 76.6% of the doctors were unsatisfied with the current treatment for liver cancer. Important factors that influenced their satisfaction with the treatment for liver cancer included early diagnosis and the disclosure of true conditions to patients.
There persists differences in the treatment of liver cancer in China, besides barriers to treatment. More attention should be paid to the detection and treatment of liver cancer and the propagation of novel progress among doctors in underdeveloped areas.
肝癌是全球范围内严重的公共卫生问题，在中国的疾病负担相对高于西方世界。尽管中国在肝癌治疗方面取得了显著进展，但在肝癌医疗服务的某些方面，不同地区和医院之间可能仍存在潜在差异。这就需要认真考虑肝癌治疗的实际状况和障碍。我们旨在探讨肝癌治疗，特别是晚期肝癌治疗的现状和障碍。
2021 年 2 月，采用自填式在线问卷对中国大陆 31 个省的 1500 名医生进行了一项全国多中心横断面研究。参与者完成了关于他们一般信息、对肝癌治疗现状的看法以及对未来治疗期望的问卷。采用卡方检验和 logistic 回归分析来探讨与地区、医生专业职称和医院级别相关的差异。
不同经济地区和不同级别医院的治疗条件、药物和治疗策略存在差异。在治疗障碍方面，76.6%的医生对目前的肝癌治疗不满意。影响他们对肝癌治疗满意度的重要因素包括早期诊断和向患者如实告知病情。
中国的肝癌治疗存在差异，除了治疗障碍外。应更加关注欠发达地区医生对肝癌的检测和治疗以及新进展的传播。
